Human Factor VIII coagulant protein (FVIII:C) has been prepared in milligram amounts from commercial FVIII concentrate by immunoadsorbent chromatography. Although this FVIII:C was partially proteolyzed, it was used to identify an amino terminal Msubr 92,000 and a carboxyl terminal Msubr 72,000 polypeptide and provide evidence for their functional importance. More recently, native, unproteolyzed FVIII:C has been partically purified on an analytical scale. Nine monoclonal antibodies have been raised against purified FVIII:C and used in Western blotting to construct a preliminary epitope map of FVIII:C: three of these antibodies reacted with the amino terminal Msubr 54,000 thrombin-derived fragment of the Msubr 92,000 chain; one reacted with the Msubr 44,000 thrombin fragment of the Msubr 92,000 chain; two had epitopes in the middle section of the molecule; and three had epitopes on a short peptide segment adjacent to the carboxyl terminal Msubr 72,000 chain. Two of these antibodies, one against the Msubr 54,000 and one against the segment adjacent to the Msubr 72,000 chain were strong neutralizers of FVIII:C activity. Similar Western blotting experiments using three inhibitor plasmas have been performed. Two inhibitors react with the Msubr 72,000 carboxyl terminal FVIII:C chain. The other inhibitor reacts with the Msubr 44,000 thrombin fragment and the Msubr 72,000 chain. The goals of this project are: determination of the reactivity of inhibitors from individuals with hemophilia A with purified FVIII:C and thrombin-degraded purified FVIII:C, using Western blotting and HPLC peptide separation; further localization of inhibitor-reactive regions of FVIII:C by proteolytic or chemical cleavage of FVIII:C or its thrombin products; further definition of inhibitor-reactive FVIII:C fragments by competition of inhibitors with monoclonal anti-FVIII:C antibodies or polyclonal anti-FVIII:C peptide antibodies; and use of synthetic peptides of FVIII:C and antibodies to them to define inhibitor binding regions of FVIII:C and their relevance to FVIII:C function.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL035090-02
Application #
3348642
Study Section
(SRC)
Project Start
1985-09-30
Project End
1988-09-29
Budget Start
1986-09-30
Budget End
1987-09-29
Support Year
2
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
San Diego
State
CA
Country
United States
Zip Code
92037
Ware, J; MacDonald, M J; Lo, M et al. (1992) Epitope mapping of human factor VIII inhibitor antibodies by site-directed mutagenesis of a factor VIII polypeptide. Blood Coagul Fibrinolysis 3:703-16
Scandella, D; Mattingly, M; de Graaf, S et al. (1989) Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 74:1618-26
Foster, P A; Fulcher, C A; Houghten, R A et al. (1988) Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy J Clin Invest 82:123-8
Fulcher, C A; Lechner, K; de Graaf Mahoney, S (1988) Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time. Blood 72:1348-56
Shima, M; Fulcher, C A; de Graaf Mahoney, S et al. (1988) Localization of the binding site for a factor VIII activity neutralizing antibody to amino acid residues Asp1663-Ser1669. J Biol Chem 263:10198-203
Foster, P A; Fulcher, C A; Houghten, R A et al. (1988) An immunogenic region within residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J Biol Chem 263:5230-4
Fulcher, C A; de Graaf Mahoney, S; Zimmerman, T S (1987) FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 69:1475-80
Foster, P A; Fulcher, C A; Marti, T et al. (1987) A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 262:8443-6